JP4993603B2 - 有核赤血球成分を含む参照対照 - Google Patents
有核赤血球成分を含む参照対照 Download PDFInfo
- Publication number
- JP4993603B2 JP4993603B2 JP2007507373A JP2007507373A JP4993603B2 JP 4993603 B2 JP4993603 B2 JP 4993603B2 JP 2007507373 A JP2007507373 A JP 2007507373A JP 2007507373 A JP2007507373 A JP 2007507373A JP 4993603 B2 JP4993603 B2 JP 4993603B2
- Authority
- JP
- Japan
- Prior art keywords
- red blood
- cell
- component
- blood cells
- nucleated red
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 210000003743 erythrocyte Anatomy 0.000 title claims description 191
- 239000013643 reference control Substances 0.000 title claims description 42
- 210000004027 cell Anatomy 0.000 claims description 71
- 238000000034 method Methods 0.000 claims description 60
- 210000004369 blood Anatomy 0.000 claims description 54
- 239000008280 blood Substances 0.000 claims description 54
- 239000000203 mixture Substances 0.000 claims description 54
- 210000004940 nucleus Anatomy 0.000 claims description 39
- 238000005259 measurement Methods 0.000 claims description 37
- 210000000601 blood cell Anatomy 0.000 claims description 34
- 239000000725 suspension Substances 0.000 claims description 29
- 230000003287 optical effect Effects 0.000 claims description 28
- 238000000149 argon plasma sintering Methods 0.000 claims description 23
- 230000009089 cytolysis Effects 0.000 claims description 18
- 210000003855 cell nucleus Anatomy 0.000 claims description 12
- 230000003750 conditioning effect Effects 0.000 claims description 11
- 238000001514 detection method Methods 0.000 claims description 9
- 238000002847 impedance measurement Methods 0.000 claims description 9
- 230000002934 lysing effect Effects 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 239000000872 buffer Substances 0.000 claims description 5
- 239000007850 fluorescent dye Substances 0.000 claims description 5
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 125000000304 alkynyl group Chemical group 0.000 claims description 4
- 210000000170 cell membrane Anatomy 0.000 claims description 4
- 238000010186 staining Methods 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 claims description 3
- 230000008859 change Effects 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000012466 permeate Substances 0.000 claims description 3
- 125000001453 quaternary ammonium group Chemical group 0.000 claims description 3
- 239000004094 surface-active agent Substances 0.000 claims description 3
- ZMGMDXCADSRNCX-UHFFFAOYSA-N 5,6-dihydroxy-1,3-diazepan-2-one Chemical compound OC1CNC(=O)NCC1O ZMGMDXCADSRNCX-UHFFFAOYSA-N 0.000 claims description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical group C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 2
- 125000005233 alkylalcohol group Chemical group 0.000 claims description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 1
- 230000003100 immobilizing effect Effects 0.000 claims 1
- 230000002101 lytic effect Effects 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 description 79
- 239000000243 solution Substances 0.000 description 53
- 241000270722 Crocodylidae Species 0.000 description 40
- LNNWVNGFPYWNQE-GMIGKAJZSA-N desomorphine Chemical compound C1C2=CC=C(O)C3=C2[C@]24CCN(C)[C@H]1[C@@H]2CCC[C@@H]4O3 LNNWVNGFPYWNQE-GMIGKAJZSA-N 0.000 description 38
- 210000001772 blood platelet Anatomy 0.000 description 24
- 238000004458 analytical method Methods 0.000 description 22
- 239000002245 particle Substances 0.000 description 19
- 238000009826 distribution Methods 0.000 description 18
- 239000003153 chemical reaction reagent Substances 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 238000000691 measurement method Methods 0.000 description 7
- 241000271566 Aves Species 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 210000002381 plasma Anatomy 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 210000000805 cytoplasm Anatomy 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 239000000834 fixative Substances 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 210000001995 reticulocyte Anatomy 0.000 description 4
- 241000251468 Actinopterygii Species 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 3
- 108010017384 Blood Proteins Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 102000004895 Lipoproteins Human genes 0.000 description 3
- 108090001030 Lipoproteins Proteins 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical group [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 3
- 235000019688 fish Nutrition 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000003908 quality control method Methods 0.000 description 3
- -1 salt compound anion Chemical class 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 241000272814 Anser sp. Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000004873 anchoring Methods 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 238000010224 classification analysis Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000003924 normoblast Anatomy 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 238000011533 pre-incubation Methods 0.000 description 2
- 238000003672 processing method Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000013374 right angle light scattering Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- KMCRQJMZUHNLKJ-NSCUHMNNSA-N (e)-4-(4-nitrophenyl)but-3-en-2-one Chemical compound CC(=O)\C=C\C1=CC=C([N+]([O-])=O)C=C1 KMCRQJMZUHNLKJ-NSCUHMNNSA-N 0.000 description 1
- BFHKYHMIVDBCPC-UHFFFAOYSA-N 1,3,5,7-tetrahydro-[1,3]oxazolo[3,4-c][1,3]oxazol-7a-ylmethanol Chemical compound C1OCN2COCC21CO BFHKYHMIVDBCPC-UHFFFAOYSA-N 0.000 description 1
- UCANJINXHRVFJI-UHFFFAOYSA-N 3,5,7,7a-tetrahydro-1h-[1,3]oxazolo[3,4-c][1,3]oxazol-5-ylmethanol Chemical compound C1OCN2C(CO)OCC21 UCANJINXHRVFJI-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- LVDKZNITIUWNER-UHFFFAOYSA-N Bronopol Chemical compound OCC(Br)(CO)[N+]([O-])=O LVDKZNITIUWNER-UHFFFAOYSA-N 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
- 229910001573 adamantine Inorganic materials 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229960002303 citric acid monohydrate Drugs 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- SOROIESOUPGGFO-UHFFFAOYSA-N diazolidinylurea Chemical compound OCNC(=O)N(CO)C1N(CO)C(=O)N(CO)C1=O SOROIESOUPGGFO-UHFFFAOYSA-N 0.000 description 1
- 229960001083 diazolidinylurea Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- WSDISUOETYTPRL-UHFFFAOYSA-N dmdm hydantoin Chemical compound CC1(C)N(CO)C(=O)N(CO)C1=O WSDISUOETYTPRL-UHFFFAOYSA-N 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 108700019599 monomethylolglycine Proteins 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- QUBQYFYWUJJAAK-UHFFFAOYSA-N oxymethurea Chemical compound OCNC(=O)NCO QUBQYFYWUJJAAK-UHFFFAOYSA-N 0.000 description 1
- 229950005308 oxymethurea Drugs 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- WZJVQUUBEVDURL-UHFFFAOYSA-N pentanedial;phosphoric acid Chemical compound OP(O)(O)=O.O=CCCCC=O WZJVQUUBEVDURL-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000012284 sample analysis method Methods 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 238000001374 small-angle light scattering Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229940101011 sodium hydroxymethylglycinate Drugs 0.000 description 1
- CITBNDNUEPMTFC-UHFFFAOYSA-M sodium;2-(hydroxymethylamino)acetate Chemical compound [Na+].OCNCC([O-])=O CITBNDNUEPMTFC-UHFFFAOYSA-M 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/96—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume, or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Electro-optical investigation, e.g. flow cytometers
- G01N15/1456—Electro-optical investigation, e.g. flow cytometers without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals
- G01N15/1459—Electro-optical investigation, e.g. flow cytometers without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals the analysis being performed on a sample stream
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume, or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N2015/1006—Investigating individual particles for cytology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume, or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Electro-optical investigation, e.g. flow cytometers
- G01N2015/1402—Data analysis by thresholding or gating operations performed on the acquired signals or stored data
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2496/00—Reference solutions for assays of biological material
- G01N2496/05—Reference solutions for assays of biological material containing blood cells or plasma
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
- Y10T436/101666—Particle count or volume standard or control [e.g., platelet count standards, etc.]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
- Y10T436/106664—Blood serum or blood plasma standard or control
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
- Y10T436/107497—Preparation composition [e.g., lysing or precipitation, etc.]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
- Y10T436/108331—Preservative, buffer, anticoagulant or diluent
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
- Y10T436/25125—Digestion or removing interfering materials
Description
本出願は、米国特許法第119条(e)による、2004年4月7日に出願され、その全体が参考文献として本明細書中に援用されている、仮特許出願番号第60/560,236号に基く利益を請求する。
1つの側面において、本発明は有核赤血球成分を含む参照対照に関する。参照対照は、核を含む血液細胞を処理溶液で処理して、核の性質を自然の値から血液分析装置上で血液サンプルの有核赤血球をシミュレートするために好適な標的値に変更することによって得られる有核赤血球成分;及び前記有核赤血球の分析のために、前記血液分析装置に前記有核赤血球成分を送達するための好適な懸濁媒を含む。核の性質は、核のサイズ、又は光学的性質を含む。光学的性質は、光散乱特性又は上記核を蛍光色素で染色した上での蛍光特性であることができる。
1つの側面において、本発明は、有核赤血球(NRBC)成分を含む参照対照並びに有核赤血球(NRBC)成分及び血液学の対照組成物の調製方法を提供する。
1.有核赤血球を有する選択された動物種の大量の全血を、抗凝固剤を入れた容器に集める。全血を遠心分離し、そして(白血球、血小板及び血漿を含む)上層を除去する。
2.濃厚有核赤血球を緩衝等張洗浄液で3回洗浄する。
3.濃厚有核赤血球を懸濁媒で洗浄し、そして洗浄された濃厚細胞を懸濁媒に再懸濁する。好ましくは、細胞計測数は、約0.4×106〜約0.6×106細胞/μlの範囲である。
4.所定の体積の再懸濁された細胞を等体積の処理溶液に加え;上下を反転させることによってよく混合して、細胞処理懸濁液を形成し;そして該細胞処理懸濁液を処理時間の間、インキュベートして、核の性質を自然の値から標的値に変更し、そして標的値を維持することによって、再懸濁された有核赤血球を処理する。
6.処理された細胞を、遠心分離によって細胞処理懸濁液から分離する。
7.処理された細胞を血液分析装置上での分析に好適な懸濁媒に再懸濁する。
{式中、
R1は、12〜16個の炭素原子を有する、アルキル、アルケニル又はアルキニル基であり;
R2、R3、及びR4は、1〜4個の炭素原子を有するアルキル基であり;そして
X-は塩化物アニオン又は臭化物アニオンである。}
で表される、4級アンモニウム界面活性剤を含む。
R1は、10〜22個の炭素原子を有する、アルキル、アルケニル、又はアルキニル基であり、
R2は、−O−であり;そして
nは、20〜35である。}
により表されるエトキシル化アルキルアルコールを含むことができる。
ワニ赤血球を用いたNRBCアナログの調製
以下の試薬組成物を、NRBCアナログの調製のために調製した。
1.多量のワニ全血を、抗凝固剤を含む容器中に集める。該ワニ全血を遠心分離し、そして(白血球、血小板及び血漿を含む)上層を除去する。
2.濃厚ワニ赤血球をリン酸緩衝生理食塩水で3回洗浄する。
3.濃厚ワニ赤血球を懸濁媒1で洗浄し、洗浄された濃厚細胞を懸濁媒1に再懸濁する。好ましくは、細胞カウントは約0.4×106〜約0.6×106細胞/μlの範囲にある。
4.所定体積の再懸濁細胞を等体積の処理溶液1に加えることによって、再懸濁されたワニ赤血球を処理し、そして上下を反転させてよく混合して、細胞処理懸濁液を形成する。
5.細胞処理懸濁液を4℃で一夜インキュベートする。
6.冷蔵庫から細胞処理懸濁液を取り出し、1000rpmで15分間遠心分離し、上清を除去する。
7.血液分析装置上での分析のために、処理された細胞を懸濁媒3に再懸濁する。
ワニ赤血球を用いる、有核赤血球成分の調製
実施例1で使用した、多量の同じワニ全血を、以下に示す処理溶液2を使用する以外は実施例1に記載されたと同じ方法のステップで処理した。
有核赤血球成分、白血球成分、並びに赤血球及び血小板成分を含む参照対照組成物
方法:
1.所定の体積の実施例1に記載の懸濁媒1を提供する。
2.懸濁媒中に、所定量の安定化されたヒト赤血球を加える。安定化されたヒト赤血球を米国特許第4,299,726号及び同第4,358,394号に記載の方法によって調製した。
3.安定化されたヒト赤血球を含む懸濁媒中に所定量の血小板アナログを加える。血小板アナログは、米国特許第4,264,470号、同第4,389,490号及び同第4,405,719号中に記載の方法によって固定化されたヤギ赤血球から作製する。
4.白血球成分としての所定量の固定化されたガチョウ赤血球を、安定化されたヒト赤血球細胞及び血小板アナログを含む懸濁媒中に加える。
5.実施例1又は2で調製した所定量のNRBCアナログを、安定化されたヒト赤血球、血小板アナログ、及び白血球成分を含む懸濁媒中に加える。
6.ステップ5で形成した参照対照組成物を混合する。赤血球、白血球及び血小板成分の細胞濃度を調製して、ヒト全血サンプルの対応する細胞濃度をシミュレートする。NRBCアナログの細胞濃度を調製して、あるレベルの有核赤血球、好ましくは100WBCあたり1〜50の範囲のNRBC、を含む臨床サンプルをシミュレートする。
有核赤血球成分、複数の白血球亜集団成分並びに赤血球及び血小板成分を含む参照対照組成物
この参照対照組成物の作成方法は、ステップ4において所定量の複数の白血球亜集団アナログを、安定化されたヒト赤血球及び血小板アナログを含む懸濁媒中に加える以外は、実施例3において上記した方法と本質的に同じ方法である。
Claims (13)
- 有核赤血球成分を含む参照対照の作製方法であって、以下のステップ:
a)核を含む血液細胞を提供し;
b)前記血液細胞を、調整成分、溶解成分及び固定成分を含む処理溶液でワンステップで処理して、核のサイズまたは光学的性質を、自然の値から血液分析装置上で有核赤血球の核のサイズまたは光学的性質をシミュレートする標的値に変更し、そして該標的値を維持し;及び
c)ステップb)から得られた処理された血液細胞を懸濁媒中に懸濁して前記参照対照を形成すること、
を含み、前記光学的性質が、光散乱特性、軸方向光損失特性、又は蛍光色素で染色した上での前記核の蛍光特性である、前記方法。 - 前記血液細胞の前記処理が、前記血液細胞を前記処理溶液と混合して、細胞処理懸濁液を形成し、そして前記細胞処理懸濁液を、15分〜24時間、インキュベートすることである、請求項1に記載の方法。
- 核のサイズまたは光学的性質を変更するための細胞処理用組成物であって、以下の:
(a)調整成分;
(b)細胞膜を透過し、そして前記細胞処理用組成物が前記細胞核と接触していることを可能とする、溶解成分;及び
(c)前記細胞核を保存するための固定成分、
を含み、ここで、前記調整成分、前記溶解成分、及び前記固定成分が、核のサイズまたは光学的性質を自然の値から標的値に変更するためのそれぞれの所定の濃度で前記細胞処理用組成物中に存在し、前記光学的性質が、光散乱特性、軸方向光損失特性、又は蛍光色素で染色した上での前記核の蛍光特性である、
前記組成物。 - 前記調整成分が、緩衝剤、及び重量モル浸透圧調節剤を含む、請求項3に記載の細胞処理用組成物。
- エトキシル化アルキルフェノールをさらに含み、該エトキシル化アルキルフェノールは、6〜12個の炭素原子を含むアルキル基及び10〜50個のエチレンオキシド基を有する、請求項5に記載の細胞処理用組成物。
- 前記固定成分が、アルデヒド、オキサゾリジン、アルコール、環状尿素、及びそれらの組み合わせから成る群から選ばれる固定剤である、請求項3に記載の細胞処理用組成物。
- 有核赤血球成分を含む参照対照の使用方法であって、以下のステップ:
a)核を含む血液細胞を、調整成分、溶解成分及び固定成分を含む処理溶液でワンステップで処理して、核のサイズまたは光学的性質を自然の値から血液サンプルの有核赤血球の核のサイズまたは光学的性質をシミュレートする標的値に変更することによって得られた有核赤血球成分を含む参照対照を提供し;
b)前記血液細胞サンプルを分析しそして他の細胞タイプから有核赤血球を識別するために適合された血液分析装置を提供し;
c)前記有核赤血球成分の検出のために前記血液分析装置に上記対照を通し;そして
d)前記参照対照中の有核赤血球を報告する
を含み、前記光学的性質が、光散乱特性、軸方向光損失特性、又は蛍光色素で染色した上での前記核の蛍光特性である、前記方法。 - 前記有核赤血球の識別が、インピーダンス測定を用いて得られる、請求項9に記載の方法。
- 前記有核赤血球の識別が、光学的測定を用いて得られる、請求項9に記載の方法。
- 前記光学的測定が、蛍光、光散乱及び軸方向光損失の測定からなる群から選ばれる、1つ以上の測定である、請求項11に記載の方法。
- 前記有核赤血球の識別が、インピーダンス測定及び光学的測定の組み合わせを用いて得られる、請求項9に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56023604P | 2004-04-07 | 2004-04-07 | |
US60/560,236 | 2004-04-07 | ||
PCT/US2005/010789 WO2005100979A1 (en) | 2004-04-07 | 2005-03-30 | Reference control containing a nucleated red blood cell component |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2007532875A JP2007532875A (ja) | 2007-11-15 |
JP2007532875A5 JP2007532875A5 (ja) | 2010-12-24 |
JP4993603B2 true JP4993603B2 (ja) | 2012-08-08 |
Family
ID=35150118
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007507373A Expired - Fee Related JP4993603B2 (ja) | 2004-04-07 | 2005-03-30 | 有核赤血球成分を含む参照対照 |
Country Status (4)
Country | Link |
---|---|
US (2) | US7135341B2 (ja) |
EP (1) | EP1738163A4 (ja) |
JP (1) | JP4993603B2 (ja) |
WO (1) | WO2005100979A1 (ja) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005043113A2 (en) * | 2003-10-12 | 2005-05-12 | Beckman Coulter, Inc. | Method of using a reference control composition for measurement of nucleated red blood cells |
US7208319B2 (en) * | 2004-02-10 | 2007-04-24 | Beckman Coulter, Inc. | Method of measurement of nucleated red blood cells |
US7541190B2 (en) * | 2005-02-07 | 2009-06-02 | Beckman Coulter, Inc. | Method of measurement of cellular hemoglobin |
US7531357B2 (en) * | 2005-04-04 | 2009-05-12 | Bio-Rad Laboratories, Inc. | Preparation of platelet analogs |
US7354767B2 (en) * | 2006-03-16 | 2008-04-08 | Beckman Coulter, Inc. | Reference control composition containing a nucleated red blood cell component made of non-nucleated blood cells |
US7482161B2 (en) * | 2006-07-17 | 2009-01-27 | Bio-Rad Laboratories, Inc. | Preparation of a red blood cell component for a hematology control |
US7618821B2 (en) | 2007-04-13 | 2009-11-17 | Streck, Inc. | Simulated blood components and methods |
CN101451931B (zh) * | 2007-12-04 | 2013-03-27 | 深圳迈瑞生物医疗电子股份有限公司 | 血液稀释液及其使用方法 |
CN101561443B (zh) * | 2008-04-15 | 2013-08-21 | 深圳迈瑞生物医疗电子股份有限公司 | 五分类白细胞模拟物粒子、其制备方法以及含该模拟粒子的质控物和校准物 |
US20100086962A1 (en) | 2008-10-08 | 2010-04-08 | Streck, Inc. | Hematology controls and methods |
CN102109430B (zh) * | 2009-12-25 | 2013-11-06 | 深圳迈瑞生物医疗电子股份有限公司 | 有核红细胞模拟粒子,血液质控物及其制备方法和用途 |
EP3408773B1 (en) | 2016-01-28 | 2023-09-20 | Beckman Coulter, Inc. | Infection detection and differentiation systems and methods |
WO2018126499A1 (zh) * | 2017-01-05 | 2018-07-12 | 深圳迈瑞生物医疗电子股份有限公司 | 网织红细胞模拟粒子、血小板模拟粒子制备方法及质控物 |
KR20190120318A (ko) | 2017-02-28 | 2019-10-23 | 베크만 컬터, 인코포레이티드 | 상호 운용 질병 관리 시스템 |
CN110770587B (zh) | 2017-05-08 | 2023-10-20 | 拜克门寇尔特公司 | 用于裂解红细胞的组合物和方法 |
US11852640B2 (en) | 2017-10-27 | 2023-12-26 | Beckman Coulter, Inc. | Hematology analyzers and methods of operation |
US11521706B2 (en) | 2018-04-20 | 2022-12-06 | Beckman Coulter, Inc. | Testing and representing suspicion of sepsis |
US11538566B2 (en) | 2018-05-23 | 2022-12-27 | Beckman Coulter, Inc. | Sample analysis with test determination based on identified condition |
US11644464B2 (en) | 2018-04-20 | 2023-05-09 | Beckman Coulter, Inc. | Sepsis infection determination systems and methods |
CN109142761B (zh) * | 2018-09-17 | 2022-02-18 | 迪瑞医疗科技股份有限公司 | 网织红细胞模拟物及其制备方法与应用 |
CN109459372B (zh) * | 2018-10-29 | 2021-03-26 | 迪瑞医疗科技股份有限公司 | 有核红细胞模拟粒子及其制备方法与应用 |
US11796447B2 (en) | 2019-07-12 | 2023-10-24 | Beckman Coulter, Inc. | Systems and methods for using cell granularitry in evaluating immune response to infection |
CN111812012B (zh) * | 2020-06-29 | 2023-08-11 | 迈克医疗电子有限公司 | 有核红细胞区域的识别方法、装置及血液分析仪 |
WO2022051443A1 (en) * | 2020-09-03 | 2022-03-10 | Bio-Rad Laboratories, Inc. | Preparation of nucleated rbc (nrbc) analogs for use as reference hematology controls in automated hematology analyzers |
CN112945667B (zh) * | 2021-02-01 | 2024-03-26 | 海南师范大学 | 一种去除有核红细胞的血液单细胞悬液的制备方法 |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3873467A (en) | 1974-02-01 | 1975-03-25 | United Medical Lab Inc | Hematologic reference control |
US4213876A (en) | 1978-08-22 | 1980-07-22 | Coulter Electronics, Inc. | Multi-purpose blood diluent for use in electronic blood analysis instrumentation |
US4358394A (en) | 1979-05-07 | 1982-11-09 | Coulter Electronics, Inc. | Process for preparing whole blood reference controls having long term stability |
US4299726A (en) | 1979-05-07 | 1981-11-10 | Coulter Electronics, Inc. | Process for preparing whole blood reference controls having long term stability, preconditioning diluent and media therefor |
US4264470A (en) | 1979-05-07 | 1981-04-28 | Coulter Electronics, Inc. | Selecting goat erythrocytes to simulate human platelets in hematologic reference controls |
US4389490A (en) | 1981-05-29 | 1983-06-21 | Coulter Electronics, Inc. | Method of stabilizing platelets for determining multiple platelet parameters in reference control and calibrator compositions; and diluents thereof |
US4405719A (en) | 1981-05-29 | 1983-09-20 | Coulter Electronics, Inc. | Method of stabilizing platelets for determining multiple platelet parameters in reference control and calibrator compositions; diluents therefor; and combination stabilization procedures |
US4704364A (en) | 1984-05-18 | 1987-11-03 | Coulter Electronics, Inc. | Hematology control compositions for three populations of leukocytes; and methods for their preparation and use in whole blood control systems |
JPH0635972B2 (ja) * | 1986-11-27 | 1994-05-11 | 東亜医用電子株式会社 | フロ−サイトメトリ−による白血球の分類方法 |
KR970007077B1 (ko) | 1987-03-13 | 1997-05-02 | 코울터 일렉트로닉스 인커퍼레이티드 | 광산란 기술을 이용한 다중-부분식별 분석 방법 |
US5460797A (en) | 1991-05-08 | 1995-10-24 | Streck Laboratories, Inc. | Method for fixing tissues and cells for analysis using oxazolidine compounds |
US5849517A (en) | 1991-05-08 | 1998-12-15 | Streck Laboratories, Inc. | Method and composition for preserving antigens and nucleic acids and process for utilizing cytological material produced by same |
US5196182A (en) | 1991-05-08 | 1993-03-23 | Streck Laboratories, Inc. | Tissue fixative |
US5262327A (en) | 1991-05-09 | 1993-11-16 | Streck Laboratories, Inc. | White blood cell hematology control |
JP3359921B2 (ja) | 1992-02-24 | 2002-12-24 | クールター インターナショナル コーポレイション | 血液組成物用懸濁媒体及びその使用方法 |
AU665413B2 (en) | 1992-02-24 | 1996-01-04 | Coulter International Corporation | Hematology control composition for leukocyte analogs; and methods for their preparation and use |
US5263327A (en) * | 1992-03-26 | 1993-11-23 | Praxair Technology, Inc. | High recovery cryogenic rectification system |
US5559037A (en) | 1994-12-15 | 1996-09-24 | Abbott Laboratories | Method for rapid and simultaneous analysis of nucleated red blood cells |
US5879900A (en) | 1994-12-15 | 1999-03-09 | Abbott Laboratories | Method for simultaneous analysis of cell viability, nucleated red blood cells and white blood cell differentials |
US5858790A (en) | 1996-06-26 | 1999-01-12 | Abbott Laboratories | Hematology reference control and method of preparation |
US6146901A (en) | 1997-06-16 | 2000-11-14 | Hematronix, Inc. | Composition for manipulating optical and electrical properties of particles to achieve target values for such properties and methods for using the composition |
US5917584A (en) | 1997-11-21 | 1999-06-29 | Coulter International Corp. | Method for differentiation of nucleated red blood cells |
US5874310A (en) | 1997-11-21 | 1999-02-23 | Coulter International Corp. | Method for differentiation of nucleated red blood cells |
US6210969B1 (en) * | 1999-04-28 | 2001-04-03 | Coulter International Corp. | Composition and method for differentiation of basophil and eosinophil subpopulations of leukocytes in blood |
US6200500B1 (en) | 1999-08-20 | 2001-03-13 | Streck Laboratories, Inc. | Hematology control and system for multi-parameter hematology measurements |
US6221668B1 (en) | 1999-08-20 | 2001-04-24 | Streck Laboratories, Inc. | Hematology control and system for multi-parameter hematology measurements |
US6448085B1 (en) | 2001-04-13 | 2002-09-10 | Sysmex Corporation | Quality control material and calibrator for nucleated red blood cell tested on hematology analyzer |
US6472215B1 (en) | 2001-07-27 | 2002-10-29 | Coulter International Corp. | Method of analyzing nucleated red blood cells in a blood sample |
US6410330B1 (en) | 2001-07-27 | 2002-06-25 | Coulter International Corp. | Method for measurement of nucleated red blood cells |
US6569682B2 (en) | 2001-07-27 | 2003-05-27 | Coulter International Corp. | Hematology control product with increased closed vial stability |
CN1276252C (zh) | 2001-07-27 | 2006-09-20 | 贝克曼库尔特有限公司 | 有核红细胞的测量方法 |
US6573102B2 (en) * | 2001-07-27 | 2003-06-03 | Coulter International Corp. | Lytic reagent composition for determination of nucleated blood cells |
US6653137B2 (en) | 2001-12-03 | 2003-11-25 | Streck Laboratories Inc. | Hematology reference control |
US6723563B2 (en) | 2001-12-03 | 2004-04-20 | Streck Laboratories Inc. | Hematology reference control |
US7198953B2 (en) * | 2003-10-12 | 2007-04-03 | Beckman Coulter, Inc. | Method of using a reference control composition for measurement of nucleated red blood cells |
WO2005043113A2 (en) * | 2003-10-12 | 2005-05-12 | Beckman Coulter, Inc. | Method of using a reference control composition for measurement of nucleated red blood cells |
-
2005
- 2005-03-30 US US11/094,644 patent/US7135341B2/en active Active
- 2005-03-30 EP EP05735364A patent/EP1738163A4/en not_active Ceased
- 2005-03-30 WO PCT/US2005/010789 patent/WO2005100979A1/en active Application Filing
- 2005-03-30 JP JP2007507373A patent/JP4993603B2/ja not_active Expired - Fee Related
-
2006
- 2006-10-30 US US11/554,098 patent/US7285417B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20050227359A1 (en) | 2005-10-13 |
US7285417B2 (en) | 2007-10-23 |
EP1738163A1 (en) | 2007-01-03 |
US7135341B2 (en) | 2006-11-14 |
US20070072298A1 (en) | 2007-03-29 |
WO2005100979A1 (en) | 2005-10-27 |
JP2007532875A (ja) | 2007-11-15 |
EP1738163A4 (en) | 2008-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4993603B2 (ja) | 有核赤血球成分を含む参照対照 | |
JP3359921B2 (ja) | 血液組成物用懸濁媒体及びその使用方法 | |
JP3391451B2 (ja) | 白血球類縁体用の血液対照組成物,およびその調製方法および使用方法 | |
JP4549440B2 (ja) | 基準対照血液および製法 | |
JP4999681B2 (ja) | 未成熟の顆粒球成分を含む血液学の参照対照 | |
US20050048656A1 (en) | Quality control method | |
US7482161B2 (en) | Preparation of a red blood cell component for a hematology control | |
JP4945629B2 (ja) | 有核赤血球成分を含むリファレンスコントロール組成物 | |
JPH10503285A (ja) | 血液学的器具の品質コントロール法 | |
US7198953B2 (en) | Method of using a reference control composition for measurement of nucleated red blood cells | |
JP4873712B2 (ja) | 有核赤血球の測定のためのリファレンスコントロールの使用方法 | |
US6362003B1 (en) | Hematological reference control composition containing leukocyte analogs, methods of making, and uses thereof | |
US6759246B1 (en) | Hematology control composition including lymphocyte analogs and method for preparation and use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080222 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080222 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20100129 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20100129 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20100129 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20100818 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100820 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20101108 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110422 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110721 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110815 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111114 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111208 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120305 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120312 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120323 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120501 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120502 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150518 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4993603 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |